clinical trial · NCT06346509
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants
Portal Therapeutics, Inc.·phase1·completed·n = 156
Healthy Adult ParticipantsPORT-77Placebo
brief summary
A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants.
started
Apr 8, 2024
primary completion
Dec 27, 2025
completion
Jan 20, 2026
last updated
Apr 20, 2026
official title
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol